As part of our mission to tackle some of the toughest targets in drug discovery, we’ve recently expanded our early discovery capabilities to include covalent compound library screening. Our early discovery site in Leiden is already well-known for its success in first-in-class and hard-to-drug targets, and this addition reflects a growing shift in the field: covalent approaches are no longer a last resort, they are becoming a smart, mechanism-led starting point for small molecule discovery. To understand what makes covalent screening so powerful…

Molecular glues are redefining how we approach drug discovery, enabling the targeting of proteins once considered “undruggable.” Unlike traditional small molecules that bind directly to a single protein, molecular glues act as mediators, stabilizing interactions between two proteins to drive a specific biological outcome. This breakthrough mechanism is particularly valuable for targeted protein degradation (TPD) and other therapeutic…

Molecular glues represent a groundbreaking approach in drug discovery, offering the unique ability to modulate or degrade traditionally “undruggable” targets by promoting or stabilizing protein-protein interactions. Unlike conventional small molecule inhibitors, molecular glues form ternary complexes involving two proteins and a small molecule, with their effectiveness largely driven by cooperativity—the synergistic enhancement of binding affinity through protein interaction.
Despite their therapeutic promise…